Testosterone Cypionate: How to Safely Stop

Why Stopping Testosterone Cypionate Requires a Plan

Testosterone cypionate does not simply "wear off" when you stop injecting. The drug is an esterified androgen dissolved in cottonseed oil; after each intramuscular or subcutaneous injection, the cypionate ester is cleaved by tissue esterases, releasing free testosterone into circulation over roughly 7 to 8 days [1]. That long half-life means serum testosterone stays elevated for 2 to 3 weeks after the last dose, which delays the moment the HPTA even recognizes that exogenous androgen is gone.

How Testosterone Cypionate Works at the Molecular Level

Free testosterone binds androgen receptors in the hypothalamus and pituitary. That binding suppresses gonadotropin-releasing hormone (GnRH) pulses and, downstream, blunts the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [2]. With LH suppressed, Leydig cells in the testes stop producing endogenous testosterone. FSH suppression simultaneously halts Sertoli cell-driven spermatogenesis.

Within 2 to 4 weeks of starting exogenous testosterone, most men reach near-complete HPTA suppression [3]. After months or years of therapy, the pituitary can become functionally sluggish, requiring weeks to months to resume normal LH pulsatility once external androgen is removed.

What Happens the Moment You Stop

Once cypionate clears the body, serum testosterone falls sharply. The pituitary begins attempting to restart GnRH signaling, but functional recovery is not immediate. During that gap, men typically experience:

• Fatigue and low energy (sometimes severe)
• Depressed mood or irritability
• Reduced libido and erectile difficulty
• Loss of lean mass and strength gains accumulated on therapy
• Sleep disruption
• Hot flashes in some cases

The T-Trials (NEJM 2016, N=790) demonstrated that the sexual-function, vitality, and walking-distance benefits of testosterone therapy reversed upon cessation [4]. That reversal is the clinical rationale for managing discontinuation rather than stopping abruptly.

The Physiology of HPTA Recovery After TRT

Understanding recovery timelines helps set realistic expectations and guides timing of follow-up labs.

Recovery Timelines by Duration of Use

A 2020 systematic review in the Journal of Clinical Endocrinology and Metabolism examined HPTA recovery in 220 men after stopping exogenous androgens [5]. Key findings:

• Men who used testosterone for fewer than 12 months recovered endogenous production (defined as total testosterone above 300 ng/dL) in a median of 3.6 months.
• Men with more than 3 years of continuous use took a median of 8.2 months to recover; roughly 15% had not recovered to 300 ng/dL at the 12-month mark.
• Age above 45 and baseline hypogonadism before TRT independently predicted slower recovery.

These numbers apply to medically prescribed TRT. Men who used supraphysiologic doses (common in athletic contexts) may face longer timelines.

The Role of LH and FSH Trajectory

LH is the first lab to rise after TRT discontinuation, often within 4 to 6 weeks of clearing cypionate. FSH follows, typically a week or two later. Serum testosterone lags both, rising only after Leydig cells have had sufficient LH stimulation to resume steroidogenesis. Ordering LH and FSH alongside total testosterone at the 6-week post-stop mark helps distinguish slow HPTA recovery (low LH, low T) from primary testicular failure (high LH, low T), which requires a different clinical approach entirely.

Fertility and Spermatogenesis

The FDA prescribing label for testosterone products carries an explicit warning that exogenous androgens suppress spermatogenesis [6]. Clinical studies confirm that the majority of men on TRT develop azoospermia or severe oligospermia within 4 to 6 months of starting therapy [7]. Spermatogenic recovery after stopping testosterone cypionate typically lags testosterone recovery by 2 to 6 months, and some men do not fully recover sperm counts even after 12 to 24 months off therapy.

Men who want to father children after TRT should be counseled before stopping that recovery of sperm production is probable but not guaranteed, and referral to a reproductive urologist is appropriate if conception is a near-term goal.

Tapering Testosterone Cypionate: Protocols and Evidence

Should You Taper or Stop Cold Turkey?

The half-life of testosterone cypionate is approximately 7 to 8 days, meaning each successive injection builds on residual serum levels. Abrupt cessation after a standard weekly 100 mg dose leaves a serum testosterone that falls at roughly the same rate as the ester clears, regardless of whether you taper. For that reason, dose tapering alone has limited pharmacokinetic justification for managing the acute decline.

What tapering does accomplish is psychological preparation and a slower transition for men whose bodies have normalized to supraphysiologic ranges. A typical medical taper might reduce a 200 mg biweekly protocol to 100 mg for 4 weeks, then 50 mg for 4 weeks before stopping. This softens the symptom onset but does not eliminate HPTA suppression.

The HealthRX Discontinuation Framework classifies patients into three tracks based on clinical context:

Track A. Short-duration TRT (under 12 months), no fertility goal. Stop testosterone cypionate without a formal taper. Begin hCG 500 IU every other day for 4 weeks. Recheck total testosterone, LH, FSH at week 6 post-final injection. If total testosterone is above 400 ng/dL and the patient is asymptomatic, discharge from protocol.

Track B. Long-duration TRT (over 12 months) or symptomatic withdrawal expected. Taper cypionate dose by 50% every 4 weeks over 8 weeks. Initiate hCG 500 to 1,000 IU every other day concurrently with the taper start date, continue for 6 weeks post-final dose. Add clomiphene citrate 25 mg daily for the final 4 weeks of hCG and for 4 weeks after hCG is stopped. Recheck labs at 6 weeks and 12 weeks post-final injection.

Track C. Fertility-driven discontinuation. Refer to reproductive urology alongside initiating Track B. Consider semen analysis at baseline (while still on TRT to document suppression), then at 3 months and 6 months post-stop. HCG may be continued at fertility-supporting doses (1,500 to 3,000 IU three times per week) for up to 6 months under specialist guidance.

hCG as a Recovery Agent

Human chorionic gonadotropin (hCG) mimics LH at the Leydig cell receptor, directly stimulating endogenous testosterone synthesis without waiting for pituitary recovery [8]. This makes it the first-line agent for bridging the gap between stopping exogenous testosterone and resuming natural production.

A randomized controlled study by Coviello et al. Published in the Journal of Clinical Endocrinology and Metabolism (N=29) demonstrated that hCG 125 to 500 IU every other day maintained intratesticular testosterone concentrations comparable to those seen without exogenous androgen suppression [9]. Doses above 500 IU every other day did not further increase intratesticular levels but did raise serum estradiol, which can cause gynecomastia and mood changes.

Practical hCG dosing in a discontinuation protocol: 500 IU every other day for 4 to 6 weeks. Monitor serum estradiol at week 3 and adjust downward if estradiol exceeds 40 pg/mL.

Clomiphene Citrate as a Second-Line Agent

Clomiphene citrate is a selective estrogen receptor modulator (SERM) that blocks estrogen's negative feedback at the hypothalamus, thereby increasing endogenous GnRH and LH secretion [10]. Unlike hCG, clomiphene works upstream, stimulating the pituitary rather than the testis directly.

A 2003 prospective study by Guay et al. (Journal of Andrology, N=36) showed that clomiphene 25 to 50 mg daily raised mean serum total testosterone from 247 ng/dL to 610 ng/dL over 3 months in hypogonadal men with secondary hypogonadism [11]. In post-TRT recovery, clomiphene is used not to replace testosterone long-term but to accelerate central axis reactivation.

Adverse effects to monitor: visual disturbances (rare but an indication to stop immediately), mood changes, and elevated estradiol if aromatization is brisk. Clomiphene is not FDA-approved for male hypogonadism, so its use in this context is off-label.

Anastrozole: When and Whether to Use It

Some discontinuation protocols include anastrozole, an aromatase inhibitor, to control the estradiol rise that can accompany hCG use. The evidence base for routine anastrozole use in post-TRT recovery is thin, and the Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism does not recommend aromatase inhibitors as primary recovery agents [12]. Anastrozole may be added selectively in men who develop symptomatic hyperestrogenism (breast tenderness, fluid retention, mood changes) during hCG therapy, at a dose of 0.5 mg twice weekly while estradiol monitoring continues.

Monitoring Labs During and After Discontinuation

Clear lab benchmarks reduce clinical uncertainty and reassure patients that recovery is progressing.

Baseline Labs Before the Final Injection

Obtain the following before stopping cypionate:

• Total testosterone (trough, drawn just before the scheduled injection)
• Free testosterone
• LH and FSH (will be suppressed; this documents baseline suppression depth)
• Estradiol (sensitive assay)
• CBC with hematocrit (TRT raises red cell mass; resolution takes 3 to 6 months)
• PSA (if age 40 or older)
• Comprehensive metabolic panel

6-Week Post-Stop Labs

At 6 weeks after the final testosterone cypionate injection:

• Total and free testosterone
• LH and FSH
• Estradiol

LH rising above 4 mIU/mL at 6 weeks is a favorable sign. If LH remains suppressed below 2 mIU/mL alongside low testosterone, the HPTA is not recovering on its own and continued adjunctive therapy is warranted.

12-Week Post-Stop Labs

By 12 weeks, most men in Track A will have recovered a total testosterone above 350 ng/dL. Men still below 300 ng/dL at 12 weeks need individualized reassessment: continued clomiphene therapy, evaluation for primary hypogonadism, or a frank conversation about returning to TRT as a long-term medical treatment rather than a temporary intervention.

The American Urological Association's 2018 Guidelines on Testosterone Deficiency state: "Patients considering stopping testosterone therapy should be counseled that natural testosterone levels may not return to pre-treatment levels, especially after long-term use." [13]

Managing Symptoms During the Transition

Discontinuation symptoms are real and can be severe. Knowing what to expect, and how to address each symptom, improves adherence to the recovery protocol.

Fatigue and Mood

Low testosterone and low estradiol during the recovery period both contribute to fatigue and depressed affect. Structured aerobic exercise three to four times per week has been shown to modestly raise endogenous LH pulsatility and support mood during this period [14]. Sleep hygiene optimization (consistent sleep schedule, limiting alcohol, reducing blue-light exposure after 9 PM) is not a pharmacologic fix but consistently reduces subjective fatigue scores in testosterone-deficient men.

If depression is clinically significant, defined as PHQ-9 score above 10 persisting beyond 6 weeks off TRT, referral to psychiatry is appropriate. Endocrine disruption-related mood disorders sometimes require concurrent treatment.

Libido and Sexual Function

Most men notice the sharpest decline in libido between weeks 3 and 8 after the final injection, as cypionate fully clears and HPTA recovery has not yet compensated. Patient education about this predictable window reduces anxiety-driven premature return to TRT.

Phosphodiesterase-5 inhibitors (sildenafil, tadalafil) can address erectile function mechanically during recovery without interfering with HPTA reactivation.

Hematocrit Normalization

Testosterone cypionate raises erythropoietin, which increases red cell mass and hematocrit [15]. Elevated hematocrit (above 54% is the FDA threshold for dose adjustment) takes 3 to 6 months to normalize after stopping therapy. Patients should avoid high-altitude living, prolonged dehydration, or concurrent use of EPO or diuretics during this period. Repeat CBC at 12 weeks post-stop.

Special Populations and Considerations

Men With Pre-Existing Primary Hypogonadism

Men who started TRT because of Klinefelter syndrome, orchitis, or surgical castration have no residual Leydig cell reserve. These patients cannot recover endogenous testosterone production regardless of how long they wait or what adjunctive agents they use. Stopping TRT in this population is only appropriate when benefits no longer outweigh risks, and the transition plan must include management of long-term androgen deficiency rather than a recovery protocol.

Men Over 60

The T-Trials enrolled men aged 65 and older with total testosterone below 275 ng/dL [4]. Baseline testosterone in this population was already substantially below normal. Even after full HPTA recovery, most men over 60 who stop TRT will return to the hypogonadal range because their pre-treatment testosterone was low to begin with. Age-related decline in Leydig cell number and function is progressive and does not reverse. Clinicians should set realistic expectations: "recovery" in this population often means returning to a symptomatic hypogonadal state rather than achieving normal testosterone.

Adolescents and Young Adults

TRT prescribed for delayed puberty or congenital hypogonadotropic hypogonadism in adolescents requires specialist management of any discontinuation. The Endocrine Society Pediatric Endocrine guidelines recommend pulsatile GnRH or gonadotropin therapy rather than testosterone for fertility preservation in this group [16]. Standard adult discontinuation protocols are not appropriate here without specialist oversight.

Practical Patient Checklist Before Your Final Injection

Use this checklist to confirm readiness to begin the discontinuation process:

1. Labs obtained (baseline testosterone trough, LH, FSH, estradiol, CBC, PSA if indicated).
2. Prescribing clinician has reviewed and approved the discontinuation track (A, B, or C).
3. HCG prescription filled and injection technique confirmed with nursing or pharmacy.
4. Clomiphene prescription in hand if Track B or C.
5. 6-week and 12-week lab appointments scheduled before stopping.
6. Patient has read and acknowledged that full recovery may take 3 to 12 months.
7. Fertility goal documented and reproductive urology referral placed if applicable.
8. PHQ-9 or equivalent depression screen completed at baseline for comparison if mood worsens.